Dyspnoea ‐ CRQ dyspnoea Scale 1 to 7. Higher is better and 0.5 units is a clinically important difference · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Adverse eventsd · patients with chronic obstructive pulmonary disease
1 finding from 1 review
CAT score · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Change in dyspnoea score · patients with chronic obstructive pulmonary disease
2 findings from 1 review
Dyspnoea ‐ change in mMRC Scale 0 to 4. Lower is better and 1 unit is a clinically important difference · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Adverse eventsf · patients with chronic obstructive pulmonary disease
1 finding from 1 review
General health‐related quality of life · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Health‐related quality of life (mental) · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Units of SGRQ change from baseline · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Intervention not reported
UCVA of 20/20 or better at 12 months post treatment · adult participants (≥ 18 years) with myopia
The intervention showed no clear difference in UCVA of 20/20 or better at 12 months post treatment (low certainty).
1 finding from 1 review
RR 0.98 [0.92, 1.05]
Studies not reported
Low
Intervention not reported
Within ± 0.50 D of target refraction at 12 months post treatment · adult participants (≥ 18 years) with myopia
The intervention showed no clear difference in within ± 0.50 D of target refraction at 12 months post treatment (low certainty).
1 finding from 1 review
RR 0.93 [0.84, 1.03]
Studies not reported
Low
Intervention not reported
Loss of 1 or more lines of BSCVA at 12 months post treatment · adult participants (≥ 18 years) with myopia
It is very uncertain whether the intervention changes loss of 1 or more lines of BSCVA at 12 months post treatment (very low certainty).
1 finding from 1 review
RR 3 [0.13, 71.96]
Studies not reported
Very low
Intervention not reported
Mean spherical equivalent at 12 months post treatment · adult participants (≥ 18 years) with myopia
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Intervention not reported
Adverse outcomes ‐ corneal haze score at 12 months (grade 1.0 ‐ more prominent haze that does not interfere with visibility of fine iris details; grade 2.0 ‐ mild obscuration of iris details; grade 3.0 ‐ moderate obscuration of iris and lens; and ... · adult participants (≥ 18 years) with myopia
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Adverse outcomes ‐ glare and halo scores at 3 months (grade 0 ‐ none; grade 1 ‐ very low; grade 2 ‐ low; grade 3 ‐ moderate; grade 4 ‐ high; and grade 5 ‐ very high) · adult participants (≥ 18 years) with myopia
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Mortality (all‐cause) · people with heart failure
1 finding from 1 review
Intervention not reported
Admission to hospital (all‐cause) · people with heart failure
1 finding from 1 review
Intervention not reported
Disease‐ specific quality of life (QoL) · people with heart failure
1 finding from 1 review
Intervention not reported
HbA1c (%) · adults, adolescents and children with Type 1 or Type 2 diabetes
1 finding from 1 review
Intervention not reported
LDL cholesterol · adults, adolescents and children with Type 1 or Type 2 diabetes
1 finding from 1 review
no estimate extracted
1 study · 4 participants
Moderate